<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835224</url>
  </required_header>
  <id_info>
    <org_study_id>A6161-W</org_study_id>
    <secondary_id>VA Project #5481-08-017</secondary_id>
    <nct_id>NCT00835224</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of L-NAME and Midodrine to Increase MAP</brief_title>
  <official_title>Safety and Efficacy of L-NAME and Midodrine to Increase MAP in Persons With Tetraplegia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After a spinal cord injury the brain is no longer completely in control of the body below the
      level of injury. This affects many organs and systems in the body, we are interested in
      understanding how a spinal cord injury affects blood pressure and blood flow to the brain. We
      are going to study blood pressure while the person is seated in a wheelchair before and after
      we give the subject medications which should increase blood pressure in a laboratory setting
      and over the course of a normal day in persons with spinal cord injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood pressure regulation is compromised in persons with tetraplegia due to de-centralization
      of sympathetic cardiovascular control, associated with hypotension during upright positioning
      (7, 10, 18, 33). An alpha receptor agonist (midodrine hydrochloride) has been reported to
      raise blood pressure in persons with tetraplegia (25, 26, 30). Midodrine is the only drug
      that is presently available to treat orthostatic hypotension. In the clinical armamentarium,
      it is always beneficial to have agents from multiple drug classes to treat a condition. In
      the treatment of hypertension, several classes of drugs may be prescribed to lower blood
      pressure, alone or in combination. The clinician and patient would benefit if another class
      of drug, with a totally separate mechanism of action, were available to treat orthostatic
      hypotension. A nitric oxide synthase inhibitor (NOSi), nitro-L-arginine methyl ester
      (L-NAME), has been shown by our group to &quot;normalize&quot; blood pressure in persons with
      tetraplegia (32). The safety and efficacy of these two hypertensive agents has not been
      investigated or compared in persons with chronic tetraplegia. Although the mechanism of
      action of each of these agents is appreciated, the relative cardiovascular effect in persons
      with SCI compared with controls is not known. The study will determine the efficacy and
      safety of these two medications at restoring mean arterial pressure (MAP) during daily
      activities in persons with chronic tetraplegia. Furthermore, the implication of restoring MAP
      to normal levels (80 10 mmHg) in individuals with tetraplegia on cardiovascular, autonomic,
      hormonal and cognitive function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Blood pressure during the 4 hour period after no drug, L-NAME (IV: 1.0 mg/kg) and midodrine (PO: 10.0 mg) administration</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Orthostatic Hypotension</condition>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Midodrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A drug to treat low blood pressure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-Name</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L-Name: A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: A pill with an inactive substance that looks like the study drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-NAME</intervention_name>
    <description>A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.</description>
    <arm_group_label>L-Name</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>To treat low blood pressure.</description>
    <arm_group_label>Midodrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A pill with an inactive substance that looks like the study drug.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Spinal Cord Injured Subjects:

          -  chronic spinal cord injury (1 year post injury) with a seated MAP of 65mmHg (almost
             all individuals with tetraplegia demonstrate this)

          -  Male or female with an age of 18 - 65 years

        Control Subjects:

          -  Male or female with an age of 18 - 65 years

        Exclusion Criteria:

        Spinal Cord Injured Subjects:

          -  acute illness

          -  cardiovascular disease

          -  renal disease

          -  medications that affect the cardiovascular system

        Control Subjects:

          -  acute illness

          -  cardiovascular disease

          -  renal disease

          -  medications that affect the cardiovascular system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Wecht, EdD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Bronx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Bronx</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wecht JM, Radulovic M, Rosado-Rivera D, Zhang RL, LaFountaine MF, Bauman WA. Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia. Arch Phys Med Rehabil. 2011 Nov;92(11):1789-95. doi: 10.1016/j.apmr.2011.03.022. Epub 2011 Jul 16.</citation>
    <PMID>21762873</PMID>
  </results_reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>September 12, 2013</results_first_submitted>
  <results_first_submitted_qc>March 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 23, 2014</results_first_posted>
  <last_update_submitted>March 21, 2014</last_update_submitted>
  <last_update_submitted_qc>March 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal Cord Injury</keyword>
  <keyword>Orthostatic Hypotension</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Midodrine Hydrochloride</keyword>
  <keyword>L-NAME</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midodrine</mesh_term>
    <mesh_term>NG-Nitroarginine Methyl Ester</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>34 subjects were consented 24 completed testing. Subjects were recruited through the Center of Excellence for the Medical Consequences of Spinal Cord Injury (SCI) from June 2010 to August of 2013.</recruitment_details>
      <pre_assignment_details>Eligibility criteria were covered by the study coordinator prior to enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>All Participants visited the laboratory on 3 occasions for a 4-5 hour observation of blood pressure following administration of a non-selective inhibitor of nitric oxide synthase (L-NAME) an alpha-agonist (midodrine) or placebo. The interventions were administered in random order on separate laboratory visits.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>30 subjects were anticipated but 34 were enrolled following an IRB approval to expand the n. Increased recruitment was due to a number of subjects withdrawing from participation for various reasons listed below.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants were studied on three laboratory visits and underwent seated blood pressure assessment before and after administration of Midodrine, L-NAME or placebo, which were given in random order.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Blood Pressure</title>
        <time_frame>Blood pressure during the 4 hour period after no drug, L-NAME (IV: 1.0 mg/kg) and midodrine (PO: 10.0 mg) administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A</title>
            <description>Spinal Cord Injured participants - Seated blood pressure after administration of a nitric oxide synthase inhibitor (L-NAME)over the course of 3 hours</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B</title>
            <description>Non disabled participants seated systolic blood pressure for 3 hours after administration of a nitric oxide synthase inhibitor (L-NAME)</description>
          </group>
          <group group_id="O3">
            <title>Arm 2A</title>
            <description>Spinal cord injured participants seated systolic Blood Pressure for 3 hours after administration of midodrine or</description>
          </group>
          <group group_id="O4">
            <title>Arm 2B</title>
            <description>Non disabled participants seated systolic blood pressure for 3 hours after administration of midodrine.</description>
          </group>
          <group group_id="O5">
            <title>Arm 3A</title>
            <description>Spinal cord injured participants systolic blood pressure for 3 hours after administration of no drug</description>
          </group>
          <group group_id="O6">
            <title>Arm 3B</title>
            <description>Non disabled participants seated systolic blood pressure for 3 hours after administration of no drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" spread="17"/>
                    <measurement group_id="O2" value="112" spread="10"/>
                    <measurement group_id="O3" value="117" spread="19"/>
                    <measurement group_id="O4" value="109" spread="5"/>
                    <measurement group_id="O5" value="96" spread="12"/>
                    <measurement group_id="O6" value="109" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1A</title>
          <description>Spinal Cord Injured participants - Seated blood pressure after administration of a nitric oxide synthase inhibitor (L-NAME)over the course of 3 hours</description>
        </group>
        <group group_id="E2">
          <title>Arm 1B</title>
          <description>Non disabled participants seated systolic blood pressure for 3 hours after administration of a nitric oxide synthase inhibitor (L-NAME)</description>
        </group>
        <group group_id="E3">
          <title>Arm 2A</title>
          <description>Spinal cord injured participants seated systolic Blood Pressure for 3 hours after administration of midodrine or</description>
        </group>
        <group group_id="E4">
          <title>Arm 2B</title>
          <description>Non disabled participants seated systolic blood pressure for 3 hours after administration of midodrine.</description>
        </group>
        <group group_id="E5">
          <title>Arm 3A</title>
          <description>Spinal cord injured participants systolic blood pressure for 3 hours after administration of no drug</description>
        </group>
        <group group_id="E6">
          <title>Arm 3B</title>
          <description>Non disabled participants seated systolic blood pressure for 3 hours after administration of no drug.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study population was relatively small and were not blinded to the interventions.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jill M. Wecht</name_or_title>
      <organization>James J Peters VAMC</organization>
      <phone>718 584-9000 ext 3122</phone>
      <email>jm.wecht@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

